Two Artificial Pancreas Systems to Enter the Canadian Market Soon

Artificial pancreas (or “closed loop”) technology is used as a treatment for type 1 diabetes (T1D). The system combines a continuous glucose monitoring (CGM) device, an insulin pump and a control algorithm, which automatically sets the insulin pump basal rate according to blood sugar levels and trends. In other words, the pump adjusts insulin delivery based on blood sugar levels. So, if your blood sugar is high or trending high, your basal rate might be increased to bring your blood sugar levels back in range (or, inversely, decreased if you’re low or trending low). The goal of this system is to reduce part of the burden that people with T1D have to bear every day by helping with diabetes management around the clock.   

Right now, the Medtronic 670G system is the only commercial artificial pancreas available on the Canadian market. Health Canada has recently approved two additional systems that will be available soon: Medtronic 770G (an update of the 670G system) and Tandem Control-IQ. 

Let’s see how they compare: 

Comparison table of two upcoming artificial pancreas systems 

Medtronic 770GTandem Control-IQ
Continuous glucose monitoring device Guardian 3Dexcom G6
Number of capillary blood sugar readings required for calibrationAt least two per dayNone
Duration of CGM sensor7 days10 days
Minimum patient ageTwo years oldSix years old
Adaptive algorithmUses both a set program and an adaptive feature that adjusts according to what works and what doesn’t for the patient.No word from Tandem regarding a potential adaptive feature.
Time spent in rangeTeens: 73%
Adults: 75%
Children: No available data
Teens: 71%
Adults: 71%
Children: 67%
Data upload (e.g., time in range, administered insulin, alarms) 

*Manual: The pump must be connected to a computer. 
**Automatic: Data is uploaded in the cloud.
Manual* or automatic** upload with smartphone appManual* upload for the Tandem pump  

Automatic** upload for the Dexcom G6


Both artificial pancreas system options are approved by Health Canada and supported by rigorous research. If you’re looking to use this type of system, make sure to take your needs and insurance coverage into account.

The Tandem Control-IQ seems to offer a number of practical advantages such as the CGM system. The Medtronic 770G, which comes after the 670G, has a solid algorithm and program, and comes with a smartphone app for better diabetes management.

Did you know that you can use a DIY artificial pancreas? To learn more, read this BETTER article.

Would you like to help make new technology available to all? 

Sign up for the BETTER registry!


  • Leelarathna, L., Choudhary, P., Wilmot, E. G., Lumb, A., Street, T., Kar, P., Ng, S. M. (2020). Hybrid closed‐loop therapy: Where are we in 2021? Diabetes, Obesity and Metabolism. doi:10.1111/dom.14273

Upcoming Events

1 thought on “Two Artificial Pancreas Systems to Enter the Canadian Market Soon”

Comments are closed.